Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2020 Sep;31(9):1115-1118.
doi: 10.1016/j.annonc.2020.07.002. Epub 2020 Aug 5.

The FDA approval of pembrolizumab for adult and pediatric patients with tumor mutational burden (TMB) ≥10: a decision centered on empowering patients and their physicians

V Subbiah  1 , D B Solit  2 , T A Chan  3 , R Kurzrock  4
Affiliations
Free article
Editorial

The FDA approval of pembrolizumab for adult and pediatric patients with tumor mutational burden (TMB) ≥10: a decision centered on empowering patients and their physicians

V Subbiah et al. Ann Oncol. 2020 Sep.
Free article
No abstract available

PubMed Disclaimer

Conflict of interest statement

Disclosures VS: Research funding/grant support for clinical trials: Roche/Genentech, Novartis, Bayer, GlaxoSmithKline, Nanocarrier, Vegenics, Celgene, Northwest Biotherapeutics, Berghealth, Incyte, Fujifilm, Pharmamar, D3, Pfizer, Multivir, Amgen, Abbvie, Alfasigma, Agensys, Boston Biomedical, Idera Pharma, Inhibrx, Exelixis, Blueprint medicines, Loxo Oncology, Medimmune, Altum, Dragonfly Therapeutics, Takeda, and National Comprehensive Cancer Network, NCI-CTEP and UT MD Anderson Cancer Center, Turning Point Therapeutics, Boston Pharmaceuticals; Travel: Novartis, Pharmamar, ASCO, ESMO, Helsinn, Incyte; Consultancy/Advisory board: Helsinn, LOXO Oncology/Eli Lilly, R-Pharma US, INCYTE, QED Pharma, Medimmune, Novartis. Other: Medscape. DBS has consulted for/received honoraria from Loxo Oncology, Lilly Oncology, Pfizer, Vivideon Therapeutics, QED Therapeutics and Illumina. TAC is a co-founder of Gritstone Oncology and holds stock; receives research funding from Bristol-Myers Squibb (BMS), Pfizer, Illumina, Eisai, AstraZeneca, NysnoBio. He is a paid consultant of BMS, Illumina, AstraZeneca, An2H and holds patents for the use of TMB for prediction of clinical benefit from immune checkpoint inhibitors and receives royalties. RK receives research funding from Genentech, Merck Serono, Pfizer, Boehringer Ingelheim, TopAlliance, Takeda, Incyte, Debiopharm, Medimmune, Sequenom, Foundation Medicine, Konica Minolta, Grifols, Omniseq and Guardant, as well as consultant and/or speaker fees and/or advisory board for X-Biotech, Loxo, Neomed, Pfizer, Actuate Therapeutics and Roche, has an equity interest in IDbyDNA and CureMatch Inc, is a cofounder of CureMatch and serves on the Board of CureMatch and CureMetrix.

Comment in

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

Publication types

Substances